BeOne Medicines (BEIGF) Receivables - Other (2017 - 2023)

BeOne Medicines (BEIGF) has reported Receivables - Other for 7 consecutive years, with $1.7 million the latest figure, recorded in Q4 2023.

• On a quarterly basis, Receivables - Other fell 42.91% year-over-year to $1.7 million in Q4 2023; TTM through Dec 2023 was $1.7 million, a 42.91% decrease from a year earlier, with the FY2023 full-year figure at $1.7 million, down 42.91% from the prior year.
• Receivables - Other was $1.7 million for Q4 2023 at BeOne Medicines, up from $1.6 million in the prior quarter.
• Over five years, Receivables - Other peaked at $12.7 million in Q4 2020 and troughed at $1.3 million in Q1 2023.
• A 5-year average of $4.3 million and a median of $3.5 million in 2019 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other slumped 77.57% in 2019 and surged 554.81% in 2020, its largest moves.
• Over 5 years, Receivables - Other stood at $1.9 million in 2019, then surged by 554.81% to $12.7 million in 2020, then sank by 60.07% to $5.1 million in 2021, then tumbled by 39.85% to $3.0 million in 2022, then sank by 42.91% to $1.7 million in 2023.
• The last three Receivables - Other figures came in at $1.7 million (Q4 2023), $1.6 million (Q3 2023), and $2.0 million (Q2 2023), per Business Quant data.